AnteoTechAnteoTechAnteoTechAnteoTech
  • Home
  • About
    • BOARD OF DIRECTORS
    • MANAGEMENT TEAM
    • ADVISORY BOARDS
  • Life Science
    • ANTEOBIND
      • PUBLICATIONS
    • PRODUCTS
    • CONTRACT SERVICES
    • CASE STUDIES
    • WEBINARS
  • Energy
    • ANTEO X
    • WEBINARS
  • Newsroom
  • Investors
    • ASX ANNOUNCEMENTS
    • CORPORATE GOVERNANCE & COMPANY POLICY
    • VIEW ON ASX
  • Customer Login
  • Contact

Case Studies

APPLICATION CASE STUDIES

White Paper


AnteoBind technology for evaluating SARS-CoV-2 variants in a Multiplex ACE2-RBD inhibition assay

The white paper discusses the use of AnteoBind technology for evaluating SARS-CoV-2 variants in a Multiplex ACE2-RBD inhibition assay (RBDCoVACE2) performed at the NMI Natural and Medical Sciences Institute at the University of Tübingen, Germany. The findings were published in Nature Scientific Reports in a paper titled: COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants.

Download White Paper Here →

Case Study: Ellume


Supporting the success of new test development with AnteoBind and Assay Contract Services

The Ellume AnteoTech relationship goes back over seven years. Ellume makes use of AnteoTech’s unique AnteoBind™ technology to support significantly improved sensitivity in a number of tests, including Ellume’s COVID-19 Home Test. The two companies have a strong partnership and are actively discussing further development opportunities to deliver diagnostic solutions to the market.

Download Case Study Here →

DCN Diagnostics


5 x More Sensitivity And Less Variation In Results With Magnetic Particles

The Anteo technology based magnetic particle hCG lateral flow assay produced a comparable limit of detection to the optimised colloidal gold reference assay of ~25 mIU/mL in urine. This confirms that particles conjugated with the Anteo Activation Reagent can rival traditionally used gold colloids in lateral flow applications and bring with it benefits associated with cost, handling and manufacturability improvements. The Anteo technology based hCG assay is 5 times more sensitive than the covalently conjugated magnetic particle based test using the same critical reagents.

Case Study: Ellume


For Ellume, there was an unmet and critical need for a faster, simpler, reliable way to diagnose and manage influenza. The technology that Ellume developed to meet this need evolved over several years and consisted of several layers of innovation. Investment in the core science has been significant and has resulted in multiple patent families with supporting national-phase applications. Around this core science, Ellume wrapped simple, intuitive user interfaces with smart-device connectivity to create unique products.

Kristin Cederquist, IMRA America


Using Anteo’s Activation Reagent to Functionalize Bare Gold Nanoparticles

The Anteo protocol process is easy to follow and implement, and it takes the guesswork out of bioconjugation, thereby saving time and biological material. I like that the system emulates biology and takes advantage of many weak interactions versus one strong, covalent bond. I would definitely use Anteo’s technology again and would like to expand its use to our other lines of nanoparticles that we are developing for IVD.

Bjorn Eckberg, Life Assays AB


Microparticles Coupled Using Anteo's Technology

We have used the Anteo's technology for the preparation of in-vitro diagnostic reagents. The Anteo method for immobilisation of antibodies is advantageous in many ways: it is much faster than many other methods; it is much easier than many other methods; last but not least it makes use of considerably fewer hazardous chemicals which in turn decreases the health risks and waste of hazardous chemicals.

NMI, Natural And Medical Sciences Institute


Coupling Antibodies And Challenging Proteins To Luminex® Magplex® Microspheres

We demonstrated the AMG Activation Kit is easy to use, which can contribute to decreased lot-to-lot variation of different assay productions, and provides an alternative chemistry for the immobilisation of challenging proteins.

Quick Links

  • About
  • Life Science
  • Energy
  • Customer Login

Investors

  • ASX Announcements
  • Corporate Governance & Company Policy
  • Financial Reporting
  • Share Price Information

Contact Us

If you have any general questions about our products or technology, contact customer support on (07) 3219 0085 or email contact@anteotech.com. For all technical support, please email support@anteotech.com.

For all investor-related queries please email investors@anteotech.com.

Copyright © AnteoTech 2021. All rights reserved. AnteoCoat/AnteoBind are trademarks of the AnteoTech group of companies. All other trademarks referenced are owned by their respective companies.
Website by Start Digital
  • Home
  • About
    • BOARD OF DIRECTORS
    • MANAGEMENT TEAM
    • ADVISORY BOARDS
  • Life Science
    • ANTEOBIND
      • PUBLICATIONS
    • PRODUCTS
    • CONTRACT SERVICES
    • CASE STUDIES
    • WEBINARS
  • Energy
    • ANTEO X
    • WEBINARS
  • Newsroom
  • Investors
    • ASX ANNOUNCEMENTS
    • CORPORATE GOVERNANCE & COMPANY POLICY
    • VIEW ON ASX
  • Customer Login
  • Contact
AnteoTech